BeOne Medicines (ONC) Notes Payables (2017 - 2025)
BeOne Medicines (ONC) reported Notes Payables of $813.3 million for Q3 2025, down 4.49% on a QoQ basis from $851.5 million in Q4 2024.
BeOne Medicines (ONC) has 4 years of Notes Payables data on file, last reported at $813.3 million in Q3 2025.
- Quarterly Notes Payables changed N/A year-over-year to $813.3 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $813.3 million (changed N/A YoY) and the FY2024 annual result came in at $851.5 million, changed N/A from the prior year.
- Notes Payables slipped to $813.3 million in Q3 2025 per ONC's latest filing, from $851.5 million in the prior quarter.
- Across five years, Notes Payables topped out at $851.5 million in Q4 2024 and bottomed at $813.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | BeOne Medicines | - | - | 1.35 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 813.30 Mn |
| Dec 31, 2024 | 851.53 Mn |
| Dec 31, 2020 | 335.02 Mn |
| Mar 31, 2017 | 2.47 Mn |